Copyright
©The Author(s) 2022.
World J Clin Cases. Jul 16, 2022; 10(20): 6825-6844
Published online Jul 16, 2022. doi: 10.12998/wjcc.v10.i20.6825
Published online Jul 16, 2022. doi: 10.12998/wjcc.v10.i20.6825
Table 1 Baseline complete blood count measurements and anamnestic data of the 835 colorectal cancer patients
| Parameter | mean ± SD or number of observations | Number of missing | Available |
| Age (yr) | 65.31 ± 11.00 | 0 | 100% |
| Male: Female | 468: 367 (56.05%: 43.95%) | 0 | 100% |
| White blood cell count (109/L) | 8.74 ± 3.55 | 0 | 100% |
| Neutrophil count (109/L) | 6.25 ± 3.37 | 169 | 79.76% |
| Eosinophil count (109/L) | 0.18 ± 0.37 | 173 | 79.28% |
| Basophil count (109/L) | 0.04 ± 0.03 | 173 | 79.28% |
| Monocyte count (109/L) | 0.56 ± 0.29 | 147 | 82.40% |
| Lymphocyte count (109/L) | 1.69 ± 0.78 | 147 | 82.40% |
| Red blood cell count (1012/L) | 4.50 ± 0.58 | 0 | 100% |
| Hemoglobin (g/L) | 122.34 ± 23.97 | 0 | 100% |
| Hematocrit (L/L) | 0.38 ± 0.06 | 0 | 100% |
| Mean corpuscular volume (fL) | 83.45 ± 9.71 | 0 | 100% |
| Mean corpuscular hemoglobin (pg) | 27.15 ± 4.12 | 0 | 100% |
| Mean corpuscular hemoglobin concentration (g/L) | 324.25 ± 24.05 | 0 | 100% |
| Red blood cell distribution width (%) | 14.95 ± 2.86 | 62 | 92.57% |
| Platelet count (109/L) | 341.19 ± 131.66 | 0 | 100% |
| AJCC stage[21] | 0 | 100% | |
| I | 107 (12.81%) | ||
| II | 214 (25.63%) | ||
| III | 187 (22.40%) | ||
| IV | 327 (39.16%) | ||
| Regional lymph node metastasis | 445 (%) | 0 | 100% |
| Distant metastasis | 0 | 100% | |
| At the time of diagnosis | 326 (39.04%) | ||
| Later with the course of the disease | 102 (12.22%) | ||
| Location of the tumor[22] | 0 | 100% | |
| Left-sided | 273 (32.69%) | ||
| Right-sided | 246 (29.46%) | ||
| Rectum | 297 (35.57%) | ||
| Multiplex | 19 (2.28%) | ||
| Chemotherapy | 0 | 100% | |
| Adjuvant | 248 (29.70%) | ||
| Metastatic | 331 (39.64%) | ||
| First line | 126 (15.09%) | ||
| Second line | 98 (11.74%) | ||
| Third line or above | 104 (12.46%) | ||
| Radiotherapy | 0 | 100% | |
| Preoperative | 63 (7.54%) | ||
| Postoperative | 64 (7.66%) | ||
| Both | 5 (0.60%) | ||
| Usage of | 0 | 100% | |
| Biological agents | 229 (27.43%) | ||
| Regorafenib/trifluridine-tipiracil | 55 (6.59%) | ||
| Medical history | 0 | 100% | |
| Diabetes mellitus | 210 (25.15%) | ||
| Hypertension | 568 (68.02%) | ||
| Major cardiovascular event(s) prior to CRC | 156 (18.68%) | ||
| Thyroid disease (in euthyroid state) | 84 (10.06%) | ||
| Appendicitis/appendectomy | 145 (17.36%) | ||
| Cholelithiasis/cholecystectomy | 194/123 (23.23%)/(14.73%) | ||
| Concomitant therapy | 0 | 100% | |
| Platelet aggregation inhibition | 158 (18.92%) | ||
| Statin | 155 (18.56%) | ||
| Antihypertensive agents | 530 (63.47%) |
- Citation: Herold Z, Herold M, Lohinszky J, Szasz AM, Dank M, Somogyi A. Longitudinal changes in personalized platelet count metrics are good indicators of initial 3-year outcome in colorectal cancer. World J Clin Cases 2022; 10(20): 6825-6844
- URL: https://www.wjgnet.com/2307-8960/full/v10/i20/6825.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v10.i20.6825